Clinical trials: Controlled Hypertension
Pulmonary Arterial Hypertension, Pulmonary Hypertension
Sitaxsentan Efficacy And Safety Trial With A Randomized Prospective Assessment Of Adding Sildenafil (SR-PAAS)
This protocol is for subjects with pulmonary arterial hypertension and is the first of 3 studies forming the Sitaxsentan efficacy and safety trial with Randomized Prospective Assessment of Adding Sildenafil (SR-PAAS) program.
- Trial name
- NCT00795639
- Testing
- Sitaxsentan
- Where
- 85 sites in United States, Argentina and 22 more
- Volunteers
- 183 people
- Sponsor
- Pfizer
Renal Pelvis Cancer, Restless Legs Syndrome
Gabapentin and Risk of Pancreatic Cancer and Renal Cancer (GPRD)
High doses of gabapentin are associated with pancreatic acinar cell tumors in rats, but there has been no post marketing pancreatic carcinogenicity signal with gabapentin as reported by spontaneous reports in the Adverse Events…
- Conditions
- Renal Pelvis Cancer, Restless Legs Syndrome, Epilepsy, Neuropathic Pain
- Trial name
- NCT01138124
- Testing
- Gabapentin prescriptions
- Volunteers
- 54,202 people
- Sponsor
- GlaxoSmithKline
Hypertension
Financial Incentives to Translate ALLHAT Into Practice: A Randomized Trial
The purpose of this study was to determine whether financial incentives for guideline-recommended treatment of hypertension are effective.
- Trial name
- NCT00302718
- Testing
- Physician-level financial incentives, Practice-level financial incentives, Physician- and practice-level financial incentives
- Where
- 12 sites in United States
- Volunteers
- 83 people
- Sponsor
- VA Office of Research and Development
Pulmonary Hypertension
The Efficacy and Safety of Sildenafil Citrate Used in Combination With Intravenous Epoprostenol in PAH
Determination of the effects of sildenafil citrate and epoprostenol when used in combination in patients with pulmonary arterial hypertension
- Trial name
- NCT00159861
- Testing
- Sildenafil citrate
- Where
- 52 sites in United States, Belgium and 9 more
- Volunteers
- 267 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Ocular Hypertension, Open-angle Glaucoma
Double-masked Study of AR-13324 Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension
To evaluate the ocular hypotensive efficacy and ocular and systemic safety of AR-13324 Ophthalmic Solution, 0.02% compared to the active comparator Timolol maleate Ophthalmic Solution, 0.5%
- Trial name
- Rocket-1 (NCT02207491)
- Testing
- Timolol maleate Ophthalmic Solution 0.5% BID, AR-13324 Ophthalmic Solution 0.02%
- Where
- United States
- Volunteers
- 411 people
- Sponsor
- Aerie Pharmaceuticals
Hypertension
COmmuNity-engaged SimULation Training for Blood Pressure Control
The goal of CONSULT-BP is to train early-stage healthcare providers, including residents and nurse practitioner (NP) students, to mitigate providers' bias, improve communication skills, and enhance providers' ability to develop…
- Trial name
- CONSULT-BP (NCT03375918)
- Testing
- CONSULT-BP Educational Intervention
- Where
- 4 sites in United States
- Volunteers
- 118 people, healthy volunteers welcome
- Sponsor
- University of Massachusetts, Worcester
Diabetes, Hypertension
Can Group Visits Improve Outcomes of Veterans With Diabetes
Background: Diabetes is a common, morbid and expensive disease among veterans. Achieving adequate glycemic control and blood pressure control can reduce the devastating complications of diabetes.
- Trial name
- NCT00286741
- Testing
- Diabetes Group Management Visits
- Where
- 2 sites in United States
- Volunteers
- 239 people
- Sponsor
- US Department of Veterans Affairs
Persistent Pulmonary Hypertension of the Newborn
Remodulin as Add-on Therapy for the Treatment of Persistent Pulmonary Hypertension of the Newborn
This study assessed the safety and treatment effect of intravenous (IV) Remodulin as an add-on therapy in neonates with persistent pulmonary hypertension of the newborn (PPHN).
- Trial name
- NCT02261883
- Testing
- IV Remodulin
- Where
- 14 sites in United States
- Volunteers
- 42 people
- Sponsor
- United Therapeutics
Ocular Hypertension, Open-angle Glaucoma
Evaluation of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma and Ocular Hypertension
Evaluation of the ocular hypotensive efficacy and safety of Netarsudil (AR-13324) Ophthalmic Solution compared to Timolol Maleate Ophthalmic Solution
- Trial name
- NCT02207621
- Testing
- AR-13324 Ophthalmic Solution 0.02%, Timolol maleate Ophthalmic Solution 0.5% BID, AR-13324 Ophthalmic Solution 0.02% BID
- Where
- United States
- Volunteers
- 756 people
- Sponsor
- Aerie Pharmaceuticals
Glaucoma and Ocular Hypertension
A Phase III Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Glaucoma or Ocular Hypertension - Spectrum 4 Study
This is a Phase III, randomized, double-masked, active-controlled, parallel-group, multi-center study. Subjects diagnosed with glaucoma or OHT who meet eligibility criteria at Visit 1 (Screening) will washout of their current…
- Trial name
- NCT03691662
- Testing
- DE-117 Ophthalmic Solution, Timolol Maleate Ophthalmic Solution 0.5%
- Where
- 34 sites in United States
- Volunteers
- 417 people
- Sponsor
- Santen Inc.
Pulmonary Hypertension
The "VISION" Trial: Ventavis Inhalation With Sildenafil to Improve and Optimize Pulmonary Arterial Hypertension
The purpose of this multi-center international trial is to evaluate the safety and effectiveness of adding iloprost or placebo (an inactive substance that contains no active study drug) to sildenafil therapy for pulmonary…
- Trial name
- VISION (NCT00302211)
- Testing
- Inhaled Iloprost (5 μg), Sildenafil, Bosentan
- Volunteers
- 67 people
- Sponsor
- Actelion
Pulmonary Hypertension
FREEDOM - M: Oral Treprostinil as Monotherapy for the Treatment of Pulmonary Arterial Hypertension (PAH)
This study was an international, multicenter, randomized (2:1 active:placebo), double-blind, placebo-controlled study in subjects with PAH who were NOT currently receiving approved therapy for their PAH.
- Trial name
- NCT00325403
- Testing
- Oral treprostinil (UT-15C) Sustained Release Tablets
- Where
- 77 sites in United States, Austria and 11 more
- Volunteers
- 349 people
- Sponsor
- United Therapeutics
Proteinuria
An Extension Study Designed to Assess Effects of Losartan on Proteinuria in Pediatric Populations (MK-0954-326 AM1,EXT1(AM2))
The purpose of this study is to evaluate the effects of losartan on proteinuria in pediatric patients.
- Trial name
- NCT00568178
- Testing
- Losartan Potassium, Comparator: amlodipine besylate
- Volunteers
- 306 people
- Sponsor
- Organon and Co
Hypertension
Hypertension Intervention Nurse Telemedicine Study (HINTS)
There are 65 million Americans and over 8.5 million veterans who have been diagnosed with hypertension; yet only 31% of all hypertensive patients have their blood pressure (BP) under effective control (less than 140/90 mm/Hg).
- Trial name
- NCT00237692
- Testing
- Nurse Behavioral intervention with Home BP Telemonitoring, Nurse Medication Management with Home BP Telemonitoring, Nurse Combined intervention with Home BP Telemonitoring
- Where
- United States
- Volunteers
- 591 people
- Sponsor
- US Department of Veterans Affairs
Cardiovascular Diseases, Heart Diseases
Preventing Weight Gain and Controlling Blood Pressure During Smoking Cessation in Hypertensive Smokers
The purpose of this study is to develop effective interventions that assist individuals with high blood pressure to quit smoking and prevent weight gain.
- Conditions
- Cardiovascular Diseases, Heart Diseases, Hypertension
- Trial name
- NCT00113074
- Testing
- Nicotine Replacement Therapy, Diet
- Where
- 2 sites in United States
- Volunteers
- 139 people
- Sponsor
- Mark Vander Weg
Pulmonary Hypertension
FREEDOM-C: Oral Treprostinil in Combination With an Endothelin Receptor Antagonist (ERA) and/or a Phosphodiesterase-5 (PDE-5) Inhibitor for the Treatment of Pulmonary Arterial Hypertension (PAH)
This study was an international, multi-center, randomized, double-blind, placebo-controlled study in subjects with PAH who were currently receiving approved therapy for their PAH (i.e., endothelin receptor antagonist and/or…
- Trial name
- NCT00325442
- Testing
- Oral treprostinil (UT-15C) sustained release tablets
- Where
- 72 sites in United States, Australia and 12 more
- Volunteers
- 354 people
- Sponsor
- United Therapeutics
Hypertension
Candesartan Cilexetil Special Drug Use Surveillance 「Challenge - Quality Control」
The purpose of this study is to gain an understanding of the actual use of candesartan cilexetil (Blopress) in patients with hypertension, and to examine the changes in parameters such as blood pressure.
- Trial name
- NCT02211638
- Testing
- Candesartan Cilexetil
- Where
- Japan
- Volunteers
- 18,113 people
- Sponsor
- Takeda
Pre-eclampsia
Efficacy Study of Digibind for Treatment of Severe Preeclampsia
The purpose of this study is to determine whether a commercially available anti-digoxin antibody, Digibind, can delay delivery in patients with severe pre-eclampsia.
- Trial name
- NCT00158743
- Testing
- Anti-digoxin antibody (FAB fragment), sodium chloride
- Where
- 8 sites in United States
- Volunteers
- 51 people
- Sponsor
- BTG International Inc.
Pulmonary Arterial Hypertension
Effects of the Combination of Bosentan and Sildenafil Versus Sildenafil Monotherapy on Pulmonary Arterial Hypertension (PAH)
COMPASS-2 is a Phase 4, prospective, randomized, double-blind, placebo-controlled, event-driven study evaluating the effect of bosentan on the time to first confirmed morbidity/mortality event in patients with symptomatic PAH…
- Trial name
- Compass-2 (NCT00303459)
- Testing
- bosentan
- Volunteers
- 334 people
- Sponsor
- Actelion
Preeclampsia
Pharmacokinetics, Safety and Efficacy Study of Recombinant Antithrombin Versus Placebo in Preterm Preeclampsia
The purpose of the study is to assess the efficacy, safety and pharmacokinetics (PK) of recombinant human antithrombin (ATryn) in addition to expectant management for the treatment of preterm preeclampsia (PPE).
- Trial name
- PRESERVE-1 (NCT02059135)
- Testing
- Recombinant human antithrombin (ATryn), Normal Saline 0.9%
- Where
- 23 sites in United States
- Volunteers
- 120 people
- Sponsor
- rEVO Biologics